Visit Natera.com

Investor Relations

Set Up Alert

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
Learn More
 
Natera San Carlos

Stock Information

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Learn More

Recent News

January 6, 2022
Natera Announces Expansion Into Early Cancer Detection and Screening
Dr. Alexey Aleshin to take on new role as GM of early cancer detection at Natera AUSTIN, Texas --(BUSINESS WIRE)--Jan. 6, 2022-- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its expansion into the early cancer detection (ECD) market to
More
January 4, 2022
Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas , Jan. 4, 2022 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that it will webcast a live presentation at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 1:30 p.m. PT ( 4:30 p.m.
More
January 3, 2022
Recent New York Times Coverage
We are aware of a New York Times story published recently, which is focused on non-invasive prenatal screening for microdeletion syndromes. We want to share some additional context in order to provide the full picture. Incorrect test accuracy claim removed:  A summary of the article stated
More
January 3, 2022
Signatera™ Wins Fierce Life Sciences Innovation Award
Natera's personalized MRD test selected as winner in the Medical Device Innovation category AUSTIN, Texas , Jan. 3, 2022 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that its personalized molecular residual disease (MRD)
More
December 9, 2021
Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021
AUSTIN, Texas , Dec. 9, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest findings presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas , from December 7-10, 2021 .
More
Read More

Upcoming Events

More events are coming soon.


Learn More

Past events

Read More

Recent Presentations

Learn More
The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.

Data Provided by Refinitiv. Minimum 15 minutes delayed.